Skip to main content
Gujarat Themis Biosyn Ltd. logo

Gujarat Themis Biosyn Ltd. — Investor Relations & Filings

Ticker · GUJTHEM ISIN · INE942C01045 LEI · 3358009IT99XRO254Q79 BSE.NS Manufacturing
Open in API
Filings indexed 696 across all filing types
Latest filing 2026-01-30 Regulatory Filings
Country IN India
Listing BSE.NS GUJTHEM

About Gujarat Themis Biosyn Ltd.

https://www.gtbl.in

Gujarat Themis Biosyn Ltd. specializes in the manufacture of active pharmaceutical ingredients and intermediates through advanced fermentation technology. The company focuses on the production of fermentation-based bulk drugs, with a primary product portfolio that includes Rifampicin intermediates and Lovastatin. Utilizing large-scale fermentation processes, the organization engages in strain improvement and media optimization to enhance yield and efficiency. The company operates a dedicated manufacturing facility equipped for complex biotechnological processes. Through technical collaborations with international entities, it has integrated specialized expertise in fermentation science to support the development of high-purity chemical compounds. Its operations are centered on providing essential building blocks for various therapeutic applications, maintaining a focus on technical precision and process-driven manufacturing excellence.

Recent filings

Filing Released Lang Actions
Board Meeting — Board Meeting Intimation
Regulatory Filings
2026-01-30 English
Gujarat Themis Biosyn Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 05/02/2026 ,inter alia, to consider and approve Please refer to the attachment.
Regulatory Filings Classification · 95% confidence The document is a letter from Gujarat Themis Biosyn Limited informing stock exchanges about the scheduled date of a Board meeting to consider and approve the unaudited financial results for the quarter and nine months ended December 31, 2025. It references compliance with SEBI regulations and insider trading code but does not contain any financial data or results itself. The document is an announcement of an upcoming board meeting and financial results, not the financial report or results themselves. The document length is short (2184 characters) and serves as an intimation notice. Therefore, it fits the category of Regulatory Filings (RNS) as a general regulatory announcement and compliance notice rather than a financial report or earnings release.
2026-01-30 English
The Exchange has received Disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 on January 19, 2026 for Themis Medicare Ltd
Major Shareholding Notification Classification · 100% confidence The document is a disclosure under Regulation 31 of the SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011. It details the pledge of shares by a promoter (Themis Medicare Limited) of Gujarat Themis Biosyn Limited, including specifics such as number of shares pledged, percentage of share capital, date of pledge, and the entity in whose favor shares are pledged. This type of disclosure is related to changes in substantial shareholdings or encumbrances and is a regulatory announcement to stock exchanges. It is not a financial report, earnings release, or management discussion. It fits the category of Major Shareholding Notification (MRQ) as it involves disclosure of encumbrance on promoter shares, which is a significant shareholding notification under SEBI regulations.
2026-01-20 English
Updates
Regulatory Filings Classification · 95% confidence The document is a letter addressed to stock exchanges reporting on the special window for re-lodgement of transfer requests of physical shares for the month of December 2025. It references a SEBI circular and confirms that no cases were received for re-lodgement in that month. The document is short (1793 characters) and serves as an informational report rather than a detailed financial report or regulatory filing. It does not contain financial statements, management discussion, or audit information. It is not an announcement of voting results, capital changes, or director dealings. The content aligns with a regulatory compliance update or general regulatory announcement. Given the nature and length, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2026-01-14 English
Please refer to the attachment.
Regulatory Filings
2026-01-14 English
The Exchange has received Disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 on January 14, 2026 for Themis Medicare Ltd
Major Shareholding Notification Classification · 100% confidence The document is a disclosure under Regulation 31 of the SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011, concerning the pledge of shares by a promoter. It details the encumbrance of shares, including the number of shares pledged, the date of pledge, the entity in whose favor the shares are pledged, and the reasons for the pledge. This type of disclosure is related to changes in significant share ownership or encumbrance and is typically classified as a Major Shareholding Notification (MRQ). The document is not a full financial report, earnings release, or management report, but a regulatory disclosure about share encumbrance by promoters.
2026-01-14 English

Browse filings by year

8 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.